These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32802894)

  • 1. High CXCR3 on Leukemic Cells Distinguishes
    Manukyan G; Papajik T; Mikulkova Z; Urbanova R; Kraiczova VS; Savara J; Kudelka M; Turcsanyi P; Kriegova E
    J Immunol Res; 2020; 2020():7084268. PubMed ID: 32802894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
    Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
    Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
    Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
    Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of VH gene expression in CD5+ and CD5- B-cell chronic lymphocytic leukemia.
    Maloum K; Davi F; Magnac C; Pritsch O; McIntyre E; Valensi F; Binet JL; Merle-Béral H; Dighiero G
    Blood; 1995 Nov; 86(10):3883-90. PubMed ID: 7579357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells.
    Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA
    Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia.
    Cha Z; Zang Y; Guo H; Rechlic JR; Olasnova LM; Gu H; Tu X; Song H; Qian B
    Tumour Biol; 2013 Dec; 34(6):3579-85. PubMed ID: 23807677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
    Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
    Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.
    Bashford-Rogers RJ; Palser AL; Hodkinson C; Baxter J; Follows GA; Vassiliou GS; Kellam P
    Exp Hematol; 2017 Feb; 46():31-37.e10. PubMed ID: 27693386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders.
    Nakahashi H; Tsukamoto N; Hashimoto Y; Koiso H; Yokohama A; Saitoh T; Uchiumi H; Handa H; Murakami H; Nojima Y; Karasawa M
    Cancer Sci; 2009 Apr; 100(4):671-7. PubMed ID: 19220298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
    Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N
    Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
    Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.